News

Zoledronic acid should not be used to treat knee osteoarthritis.

Tele-rheumatology has never really been a predominate feature in rheumatology clinics, but due to the coronavirus pandemic, rheumatology clinics have begun to embrace the practice. Learn more in this interview with Dr. Andrew Concoff, Executive Vice President and Chief Value Officer of United Rheumatology.

Some rheumatology patients have very strong opinions about whether they should continue to take  immunosuppressive drugs under the threat of coronavirus. In this interview with Rheumatology Network, Dr. Andrew Concoff, Executive Vice President and Chief Value Officer of United Rheumatology, addresses the hazards of suddenly stopping these medications.

In this interview with Rheumatology Network, Dr. Andrew Concoff, Executive Vice President and Chief Value Officer of United Rheumatology, addresses best practices rheumatology practices may want to consider for managing patient visits.

In this interview with Rheumatology Network, Dr. Andrew Concoff, Executive Vice President and Chief Value Officer of United Rheumatology, discusses how the typical rheumatology patient visit has changed during the coronavirus pandemic.

Patients who have operations have increased range of motion than those who do not have surgery.

Abatacept (Orencia, Bristol Myers Squibb), a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis, appears to lower the risk of diabetes mellitus in patients with rheumatoid arthritis who are receiving biologic or targeted synthetic DMARDs.

This week, the National Institutes of Health issued treatment guidelines for the management of COVID-19. It does not include the use of pharmaceutical agents for pre or post-exposure prophylaxis, including hydroxychloroquine, except for within the confines of a clinical trial. This comes as good news to the rheumatology community. More in this article.

Patients who undergo knee chondroplasty procedures have a 17-fold increased risk of receiving knee arthroplasty than the general population.

New findings comparing 3 decades of newly approved indications show the proportion of new approvals being supported by just 1 pivotal trial has quadrupled.

Despite an apparent and increasing need for osteoporosis treatments, fewer people today are taking the medications both here in the United States and abroad.

The international registry that was created in March to track rheumatology patients who have contracted COVID-19, has released data from the first 110 cases from six continents.

United Rheumatology, a management services organization serving over 645 rheumatologists in 39 states, will host a one-day virtual clinical conference focusing on managing a rheumatology practice through the COVID-19 pandemic.

The negative impact of the COVID-19 pandemic on specialty medical practices may lift by the start of next month, according to a new report issued by the market research company Spherix Global Insights.

The American College of Rheumatology has issued treatment guidance for the care of patients with rheumatic diseases during the COVID-19 pandemic.

Jacquelyn Center, PhD, discuss with HCPLive the findings of her study and factors that increase mortality risk.

The findings provide insight into practice, provide a rubric for future studies, and suggest areas to improve resource use and patient care.

Dapansutrile has substantial potential for further development for the treatment of gout flares and other NLRP3-mediated diseases.

The blinded, placebo-controlled randomized clinical trial will seek to enroll more than 500 adult patients.

A conversation on new AI software which can identify a five-fold greater rate of potential fractures.

Physical therapy for knee osteoarthritis improves pain scores and physical function.

In this Q&A, Randy Q. Cron, M.D., Ph.D., a pediatric rheumatologist at the University of Alabama at Birmingham, discusses the role of rheumatologists in the diagnosis and treatment of patients with COVID-19, particularly those who are critically ill and experiencing a cytokine storm syndrome.

In response to the COVID-19 pandemic, the Global Rheumatology Alliance has been created to collect data on how the virus is affecting patients with rheumatic diseases or those who are taking immunosuppressive therapies. The alliance, which includes 300 rheumatologists, scientists and patients from throughout the world, has created a registry for physicians to report COVID-19 cases.

Can a patient with hidradenitis suppurativa develop rheumatoid arthritis? Apparently so, according to researchers writing in JAMA Dermatology this month.

COVID-19 is being treated with treatments designed for rheumatoid arthritis. They have their pros and cons. Learn more in this article.

Doses of secukinumab are clinically safe and beneficial for long-term treatment of psoriatic arthritis.

Shelter-in-place orders have led to a "horrifying surge in domestic violence," says the United Nations Secretary-General Antonio Guterres. The World Health Organization asks that healthcare workers be cognizant of the signs and symptoms of domestic violence in their patients. In today's "Awkward Conversations" column, Dr. Kim Gorgens and Margaret Port cover domestic violence among chronically ill patients.

A new study shows there is little to no clinical benefit in reducing TNFi treatment dosages for patients with axial spondyloarthritis (axSpA).

A comprehensive review of published studies on gut microbiota, immunity and arthritis suggests that having a microbial imbalance may precede the development of spondyloarthritides and osteoarthritis.

Investigators grapple with the viability of using chloroquine and hydroxychloroquine to stop the spread of COVID-19.